The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 335:1621-1629 November 28, 1996 Number 22
NextNext

Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant
Rhoda S. Sperling, M.D., David E. Shapiro, Ph.D., Robert W. Coombs, M.D., Ph.D., John A. Todd, Ph.D., Steven A. Herman, Ph.D., George D. McSherry, M.D., Mary Jo O'Sullivan, M.D., Russell B. Van Dyke, M.D., Eleanor Jimenez, M.D., Christine Rouzioux, Ph.D., Patricia M. Flynn, M.D., John L. Sullivan, M.D., Stephen A. Spector, Clemente Diaz, M.D., James Rooney, M.D., James Balsley, M.D., Ph.D., Richard D. Gelber, Ph.D., Edward M. Connor, M.D., for The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background and Methods A placebo-controlled trial has shown that treatment with zidovudine reduces the rate at which human immunodeficiency virus type 1 (HIV-1) is transmitted from mother to infant. We present data from that trial showing the number of infected infants at 18 months of age and the relation between the maternal viral load, the risk of HIV-1 transmission, and the efficacy of zidovudine treatment. Viral cultures were obtained, and HIV-1 RNA was measured by two assays in samples of maternal blood obtained at study entry and at delivery.

Results In 402 mother–infant pairs, the rate of transmission of HIV-1 was 7.6 percent (95 percent confidence interval, 4.3 to 12.3 percent) with zidovudine treatment and 22.6 percent (95 percent confidence interval, 17.0 to 29.0 percent) with placebo (P<0.001). In the placebo group, a large viral burden at entry or delivery or a positive culture was associated with an increased risk of transmission (the transmission rate was greater than 40 percent in the highest quartile of the RNA level). In both groups, transmission occurred at a wide range of maternal plasma HIV-1 RNA levels. Zidovudine reduced plasma RNA levels somewhat (median reduction, 0.24 log). Zidovudine was effective regardless of the HIV-1 RNA level or the CD4+ count at entry. In the zidovudine group, however, after we adjusted for the base-line HIV-1 RNA level and CD4+ count, the reduction in viral RNA from base line to delivery was not significantly associated with the risk of transmission of HIV-1.

Conclusions A high maternal plasma concentration of virus is a risk factor for the transmission of HIV-1 from an untreated mother to her infant. The reduction in such transmission after zidovudine treatment is only partly explained by the reduction in plasma levels of viral RNA. To prevent HIV-1 transmission, initiating maternal treatment with zidovudine is recommended regardless of the plasma level of HIV-1 RNA or the CD4+ count.


Source Information

From the Department of Obstetrics, Gynecology, and Reproductive Science, Mount Sinai School of Medicine, New York (R.S.S.); the Statistical and Data Analysis Center, Pediatric AIDS Clinical Trials Group, Harvard School of Public Health, Boston (D.E.S.); University of Washington School of Medicine, Seattle (R.W.C.); Chiron Corporation, Emeryville, Calif. (J.A.T.); Roche Molecular Systems, Branchburg, N.J. (S.A.H.); Department of Pediatrics, University of Medicine and Dentistry of New Jersey–New Jersey Medical School, Newark (G.D.M.); University of Miami School of Medicine, Miami (M.J.O.); Tulane University School of Medicine, New Orleans (R.B.V.); San Juan City Hospital, San Juan, P.R. (E.J.); Agence Nationale de Recherche sur le SIDA–Hôpital Necker, Paris (C.R.); St. Jude Children's Research Hospital, Memphis, Tenn. (P.M.F.); and the University of Massachusetts, Worcester (J.L.S.). Other authors were Stephen A. Spector, M.D. (University of California at San Diego Medical Center, San Diego), Clemente Diaz, M.D. (University of Puerto Rico, San Juan), James Rooney, M.D. (Glaxo Wellcome, Research Triangle Park, N.C.), James Balsley, M.D., Ph.D. (National Institute of Allergy and Infectious Diseases, Bethesda, Md.), Richard D. Gelber, Ph.D. (Harvard School of Public Health, Boston), and Edward M. Connor, M.D. (University of Medicine and Dentistry of New Jersey–New Jersey Medical School, Newark).

Address reprint requests to Dr. Sperling at Mount Sinai Medical Center, Box 1173, 1 Gustave Levy Pl., New York, NY 10029.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.